3 Results for "

Escherichia coli ACP

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "Escherichia coli ACP" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-127146
CAS No.: 835876-32-9
Purity:  95.00%
Target:  

Antibiotic Bacterial

Research Areas:  

Infection

APOL1-IN-1 is a natural product antibiotic and selective FabF inhibitor discovered in Streptomyces platensis. Platensimycin exhibits IC50 values of 48 nM and 160 nM against Staphylococcus aureus and Escherichia coli FabF, respectively. Platensimycin preferentially recognizes the acyl-enzyme conformation of FabF, occupies the malonyl-binding subsite, and competes with malonyl-ACP, thereby inhibiting bacterial fatty acid elongation. Platensimycin is useful for research on bacterial fatty acid biosynthesis and Gram-positive bacterial infections .
loading...
    loading...
Cat. No.: HY-175596
CAS No.: 1382489-31-7
Target:  

ClpP Bacterial

Research Areas:  

Infection

ACP1-01 is a bacterial ClpP activator with EC50s of 3.4 and 2.6  μM for Neisseria meningitides ClpP (NmClpP) and Escherichia coli ClpP (EcClpP). ACP1-01 noncovalently binds to ClpP C sites and activates the protease. ACP1-01 has antibacterial activity. ACP1-01 can be used for bacterial infections research .
loading...
    loading...
Cat. No.: HY-W1143867
CAS No.: 2226-71-3
4’-Phosphopantetheine is an orally active coenzyme A (CoA) precursor. 4’-Phosphopantetheine is membrane-permeable and acts as a CoA precursor, a prosthetic group, and a reactive oxygen species (ROS) inhibitor. 4’-Phosphopantetheine binds covalently to rat liver fatty acid synthase, modifies the conserved serine residue in the PKS/NRPS carrier protein domain, and serves as a substrate for CoA synthase and PPAT. 4’-Phosphopantetheine undergoes non-catalytic exchange on rat liver fatty acid synthase, with a faster turnover rate than that of the enzyme complex, and restores intracellular CoA levels in cells with impaired de novo biosynthesis. 4’-Phosphopantetheine rescues phenotypes induced by CoA deficiency, normalizes PKAN-related biomarkers, restores mitochondrial enzyme activity, and alleviates vascular endothelial damage. 4’-Phosphopantetheine shows biological stability in serum, acts as a prosthetic group and degradation product of ACP, and inhibits the formation of atherosclerotic plaques. 4’-Phosphopantetheine can be used in the research of brain iron accumulation neurodegenerative diseases, pantothenate kinase-associated neurodegeneration, CoASY protein-associated neurodegenerative diseases, coronary heart disease, and atherosclerosis .
loading...
    loading...